Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 29,300 shares, an increase of 37.6% from the February 13th total of 21,300 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 32,500 shares, the short-interest ratio is presently 0.9 days.
Wall Street Analysts Forecast Growth
Separately, UBS Group upgraded Nanobiotix to a “hold” rating in a report on Monday, February 17th.
Institutional Inflows and Outflows
Nanobiotix Trading Up 4.9 %
Shares of Nanobiotix stock traded up $0.15 on Friday, hitting $3.22. 388 shares of the company were exchanged, compared to its average volume of 22,032. The company has a 50-day moving average price of $3.43 and a 200 day moving average price of $3.97. Nanobiotix has a 1-year low of $2.76 and a 1-year high of $7.51.
Nanobiotix Company Profile
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
- Five stocks we like better than Nanobiotix
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- How to Build the Ultimate Everything ETF Portfolio
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.